This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Garcia, M. Articles by Rio, M. D. Search for Related Content PubMed PubMed Citation Articles by Garcia, M. Articles by Rio, M. D.

Inhibition of Xenografted Human Melanoma Growth and Prevention of Metastasis Development by Dual Antiangiogenic/Antitumor Activities of Pigment Epithelium-Derived Factor

¹ Project on Damage, Repair and Tissue Engineering CIEMAT and Fundación M. Botin, Madrid, Spain; ² Department of Biochemistry, Universidad Autónoma de Madrid-Instituto de Investigaciones Biomédicas CSIC-UAM, Madrid, Spain; ³ Department of Molecular and Cellular Biology and Dermatology, Huffington Center on Aging, Baylor College of Medicine, Houston, Texas; and ⁴ Northwestern University Medical School, Department of Urology, Chicago, Illinois

Human melanoma mortality is associated with the growth of metastasis in selected organs including the lungs, liver, and brain. In this study, we examined the consequences of overexpression of pigment epithelium-derived factor (PEDF), a neurotrophic factor and potent angiogenesis inhibitor, on both melanoma primary tumor growth and metastasis development. PEDF overexpression by melanoma cells greatly inhibited subcutaneous tumor formation and completely prevented lung and liver metastasis in immunocompromised mice after tail vein injection of metastatic human melanoma cell lines. Whereas the effects of PEDF on primary tumor xenografts appear mostly associated with inhibition of the angiogenic tumor response, abrogation of melanoma metastasis appears to depend on direct PEDF effects on both migration and survival of melanoma cells. PEDF-mediated inhibition of melanoma metastases could thus have a major impact on existing therapies for melanoma.

This article has been cited by other articles:

				B. Zhu, L. Lu, W. Cai, X. Yang, C. Li, Z. Yang, W. Zhan, J.-x. Ma, and G. Gao Kallikrein-binding protein inhibits growth of gastric carcinoma by reducing vascular endothelial growth factor production and angiogenesis Mol. Cancer Ther., December 1, 2007; 6(12): 3297 - 3306. [Abstract] [Full Text] [PDF]

				C.R. Dass, T.M.N. Tran, and P.F.M. Choong Angiogenesis Inhibitors and the Need for Anti-angiogenic Therapeutics J. Dent. Res., October 1, 2007; 86(10): 927 - 936. [Abstract] [Full Text] [PDF]

				L. Notari, V. Baladron, J. D. Aroca-Aguilar, N. Balko, R. Heredia, C. Meyer, P. M. Notario, S. Saravanamuthu, M.-L. Nueda, F. Sanchez-Sanchez, et al. Identification of a Lipase-linked Cell Membrane Receptor for Pigment Epithelium-derived Factor J. Biol. Chem., December 8, 2006; 281(49): 38022 - 38037. [Abstract] [Full Text] [PDF]

				E. T.H. Ek, C. R. Dass, and P. F.M. Choong Pigment epithelium-derived factor: a multimodal tumor inhibitor. Mol. Cancer Ther., July 1, 2006; 5(7): 1641 - 1646. [Abstract] [Full Text] [PDF]

				G. Maik-Rachline and R. Seger Variable phosphorylation states of pigment-epithelium-derived factor differentially regulate its function Blood, April 1, 2006; 107(7): 2745 - 2752. [Abstract] [Full Text] [PDF]

				D. M. Sidle, J. Maddalozzo, J. D. Meier, M. Cornwell, V. Stellmach, and S. E. Crawford Altered Pigment Epithelium-Derived Factor and Vascular Endothelial Growth Factor Levels in Lymphangioma Pathogenesis and Clinical Recurrence Arch Otolaryngol Head Neck Surg, November 1, 2005; 131(11): 990 - 995. [Abstract] [Full Text] [PDF]